AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11295661
Drug: Cetirizine, 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine, 0.25 mg/kg, twice daily for 18 months
Trial: 11295661
Drug: Placebo, matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, matching placebo twice daily for 18 months
Trial: 9260417
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment for dental hard tissue
Trial: 7684993
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (3 courses of the 'quick' VBP scheme)
Trial: 15036674
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no neoadjuvant chemotherapy)
Trial: 31274211
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL normal saline (placebo)
Trial: 27316324
Drug: Bedtime chronotherapy
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime chronotherapy with ≥1 conventional hypertension medications
Trial: 25808497
Drug: Compression method
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compression method (80-160 mL balloon volume)
Trial: 25808497
Drug: Standard method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard method (50 mL balloon volume)
Trial: 23931043
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum magnesium concentration (1.60‐2.50 mmol/L)
Trial: 23931043
Drug: Normal serum
RxNorm normalized name: Albumin, Normal Serum, Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal serum magnesium concentration (0.65‐1.05 mmol/L)
Trial: 20099160
Drug: Viable Bifidobacterium
RxNorm normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viable Bifidobacterium supplement
Trial: 14983963
Drug: Small focus
RxNorm normalized name: Ficus benghalensis bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small focus of well-differentiated carcinoma on biopsy with serum PSA < 4 ng/mL
Trial: 14983963
Drug: Small focus
RxNorm normalized name: Ficus benghalensis bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small focus of well-differentiated carcinoma on biopsy with serum PSA >= 4 ng/mL
Trial: 8714328
Drug: Impact of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impact of Events Scale administered to assess trauma impact
Trial: 27191165
Drug: Deferiprone, 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone, 17 oral doses, supra-threshold concentrations (150 μM)
Trial: 27191165
Drug: Deferiprone, 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone, 17 oral doses
Trial: 23254592
Drug: Bezafibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (200 mg twice daily for 8 weeks)
Trial: 18821287
Drug: Nandrolone phenpropionate
RxNorm normalized name: NANDROLONE PHENPROPIONATE
DrugBank: Nandrolone phenpropionate (DB00984)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone phenpropionate (100 mg, intramuscularly, pulse-dose)
Trial: 16018757
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5% sodium fluoride varnish and Nd:YAG laser
Trial: 8540731
Drug: Levofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (200 mg) alone
Trial: 1686184
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of riboflavin administered at night
Trial: 7334934
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of oestriol succinate per day
Trial: 7334934
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of oestriol succinate per day
Trial: 7334934
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg of oestriol succinate per day (divided into two doses)
Trial: 25040143
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (pre‐emptive) received 0.125% ropivacaine 6 mL 30 min before skin incision and every 60 min during surgery, then PCEA.
Trial: 25040143
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (routine) was given 0.125% ropivacaine 6 mL 30 min after surgery, then PCEA.
Trial: 17875948
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation, 1 g capsule for 14 days
Trial: 17875948
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 g of corn oil)
Trial: 9134786
Drug: Daily ratings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ratings of IBS symptoms for 8 weeks
Trial: 3295019
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone treatment (200 mg t.i.d.)
Trial: 17433577
Drug: Prebiotic formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic formula (0.4 g/100 ml prebiotic galacto- and long-chain fructooligosaccharides)
Trial: 16965688
Drug: DLF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DLF regimen (n=48): 2-hour infusion of folinic acid 200 mg/m(2), followed by 5-FU bolus 400 mg/m(2) and 48-hour infusion of 5-FU 3,000 mg/m(2) every 3 weeks, combined with cisplatin 80 mg/m(2)
Trial: 16965688
Drug: CLF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLF regimen (n=32): 2-hour infusion of folinic acid 200 mg/m(2), followed by 5-FU bolus 400 mg/m(2) and 48-hour infusion of 5-FU 3,000 mg/m(2) every 3 weeks, combined with carboplatin AUC=5
Trial: 16965688
Drug: DFM regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFM regimen (n=18): 2-hour infusion of folinic acid 200 mg/m(2), followed by 5-FU bolus 400 mg/m(2) on day 1-5 plus pingyangmycin 5 mg/m(2) on day 1, 3, 5
Trial: 12934407
Drug: Propofol-based total
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-based total intravenous anesthesia (Group B, n = 14)
Trial: 12934407
Drug: Isoflurane-based inhalational-intravenous
RxNorm normalized name: isoflurane Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane-based inhalational-intravenous general anesthesia (Group C, n = 14)
Trial: 10210912
Drug: nicergoline 30
RxNorm normalized name: nicergoline 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nicergoline 30 mg b.i.d.
Trial: 8726094
Drug: Beta‐adrenergic blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta‐adrenergic blocking agents
Trial: 8726094
Drug: Patients not
RxNorm normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not on beta‐blockers
Trial: 8726094
Drug: Patients on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on beta‐blockers
Trial: 7811016
Drug: Teicoplanin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (6 mg/kg once daily)
Trial: 1834010
Drug: Teicoplanin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (30 mg/kg once daily)
Trial: 1834010
Drug: Teicoplanin and
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin and vancomycin in serum ultrafiltrate and SMHB at 60 micrograms/ml
Trial: 30670099
Drug: Brief Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Group Psychoanalytic Psychotherapy (20 weeks, weekly sessions)
Trial: 28881431
Drug: SmartXide Fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SmartXide Fractional CO2 laser treatment
Trial: 26179246
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg daily for 5 days every 4 weeks
Trial: 8328549
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg/day
Trial: 24229360
Drug: Azithromycin 250
RxNorm normalized name: azithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 250 mg 3 times a week
Trial: 24080932
Drug: Reversible interocclusal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reversible interocclusal splint therapy (RIST)
Trial: 19366448
Drug: AS-SMP three-day
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS-SMP three-day regimen (once daily for 3 days) (N = 476)
Trial: 19366448
Drug: Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (AL) regular 6 doses regimen (N = 450)
Trial: 19366448
Drug: AS-SMP three-day
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS-SMP three-day regimen (once daily for 3 days)
Trial: 19366448
Drug: Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (AL) regular 6 doses regimen
Trial: 15265788
Drug: Intermediate-dose therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose therapy (2 courses of melphalan at 100 mg/m(2) with stem cell support)
Trial: 15265788
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (6 courses of oral melphalan and prednisone)
Trial: 11297574
Drug: IGF-I treatment
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-I treatment (15 microg/kg twice daily)
Trial: 11297574
Drug: IGF-I treatment
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-I treatment
Trial: 9043536
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg atropine sulfate added to the first nebulizer and saline in the second and third treatments
Trial: 9043536
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg atropine to the first and third treatments (with saline in the second)
Trial: 9043536
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo during all 3 treatments
Trial: 8196726
Drug: Cyclosporine (subsequent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (subsequent treatment for placebo non-responders)
Trial: 3286242
Drug: Fenugreek (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenugreek (15 g) soaked in water
Trial: 22622291
Drug: Ketamine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.8 mg/kg)
Trial: 27208499
Drug: Subanesthetic ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanesthetic ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg)
Trial: 24206741
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with levofloxacin, amoxicillin, and a PPI for 10 days
Trial: 24206741
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with clarithromycin for 10 days
Trial: 18513531
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg PO twice daily for a total of 14 doses (3 preoperative)
Trial: 16579728
Drug: Grapefruit capsules
RxNorm normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit capsules
Trial: 9208491
Drug: Combined drugs
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drugs (HPC + TMX, HPC + AG, TMX + AG)
Trial: 7016089
Drug: Combined fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined fluoride treatment (gel + rinse)
Trial: 7016089
Drug: Gel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel treatment
Trial: 7016089
Drug: Rinse treatment
RxNorm normalized name: Piperonyl Butoxide/Pyrethrum Extract 4%-0.33% Topical application Liquid [LICE CREME RINSE TREATMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinse treatment
Trial: 26270587
Drug: Anesthetic cream
RxNorm normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic cream applied to the forearm
Trial: 16450373
Drug: Polyvalent, shed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyvalent, shed antigen, melanoma vaccine
Trial: 16873344
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate 30 mL p.o. and saline 2 mL i.v.
Trial: 16873344
Drug: Water 30
RxNorm normalized name: dextrose 30 % in water 30 % INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water 30 mL p.o. and famotidine 20 mg i.v.
Trial: 10193813
Drug: L‐NMMA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA treatment (3 mg/kg) after pretreatment with CAND (8 mg)
Trial: 10193813
Drug: L‐NMMA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA treatment (3 mg/kg) after placebo
Trial: 10193813
Drug: L‐NMMA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA treatment (3 mg/kg)
Trial: 10451130
Drug: Indomethacin 100
RxNorm normalized name: indomethacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 100 mg suppositories
Trial: 7053160
Drug: Marihuana inhalation
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marihuana inhalation
Trial: 25246239
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg), Vitamin E (400 mg), Zinc gluconate (25 mg), Selenomethionine (200 μg)
Trial: 20963843
Drug: Biofilm testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofilm testing for antibiotic selection
Trial: 18534087
Drug: Minocycline 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 150 mg p.o. twice daily
Trial: 12885990
Drug: Heterozygosity at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterozygosity at position 27 of the β2 adrenergic receptor (ADRB2) polymorphism
Trial: 12885990
Drug: Polymorphism at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphism at position 16 of the β2 adrenergic receptor (ADRB2)
Trial: 11789186
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CAKF plus chemotherapy)
Trial: 11789186
Drug: Chemotherapy (5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (5-FU and mitomycin C)
Trial: 1892680
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide plus methylprednisolone (arm A)
Trial: 1892680
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide plus methylprednisolone plus lorazepam (arm B)
Trial: 6643694
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg dyphylline
Trial: 6643694
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg dyphylline
Trial: 6643694
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg dyphylline
Trial: 6643694
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg anhydrous theophylline
Trial: 31848050
Drug: Bivalent Oral
RxNorm normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent Oral Polio Vaccine (bOPV)
Trial: 27455513
Drug: Levomilnacipran extended-release
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomilnacipran extended-release (ER)
Trial: 17241248
Drug: Combined hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined hepatitis A and B vaccine (Twinrix) administered at 0, 7, 21 to 30 days, and 12 months
Trial: 17241248
Drug: Monovalent hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent hepatitis B vaccine (Engerix-B) administered at 0, 1, 2, and 12 months
Trial: 17241248
Drug: Monovalent hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent hepatitis A vaccine (Havrix)
Trial: 17241248
Drug: Monovalent hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent hepatitis B vaccine (Engerix-B)
Trial: 17241248
Drug: Monovalent vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent vaccines (Havrix and Engerix-B)
Trial: 15274701
Drug: Subcutaneous alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous alprostadil (low doses) with saline solution intravenously
Trial: 15274701
Drug: Intravenous alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alprostadil with local saline solution injections
Trial: 15274701
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution around the ulcers and intravenously (Control)
Trial: 11526545
Drug: Entecavir 0.05
RxNorm normalized name: entecavir 0.05 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.05 mg
Trial: 21513847
Drug: Entecavir 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.1 mg
Trial: 21513847
Drug: Entecavir 1.0
RxNorm normalized name: ENTECAVIR 1.0 mg ORAL TABLET, FILM COATED [BARACLUDE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 1.0 mg
Trial: 9248873
Drug: Moclobemide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (150 mg twice a day, doubled after 3 weeks if needed)
Trial: 9248873
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg q.a.m., doubled after 3 weeks if needed)
Trial: 30558092
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric ropivacaine (15.2 mg) with 5 μg sufentanil
Trial: 30558092
Drug: Prophylactic infusion
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic infusion of phenylephrine (50 μg/min)
Trial: 27433861
Drug: Hypertrophic resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertrophic resistance training (RT) for 6 weeks, two 40-minute sessions weekly, three sets of 12 repetitions at 67% to 85% one-repetition maximum for 10 whole-body exercises.
Trial: 22990352
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg/day)
Trial: 22990352
Drug: Add-on therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on therapy (further diuretic and other drugs)
Trial: 22990352
Drug: No-add-on therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-add-on therapy
Trial: 21109670
Drug: Values affirmation
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Values affirmation intervention (students wrote about their most important values, twice at the beginning of the course)
Trial: 12548129
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (1 g every 8 hr) after IV ganciclovir (6 mg/kg per day for 14 days)
Trial: 12548129
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (800 mg every 6 hr) after IV ganciclovir (6 mg/kg per day for 14 days)
Trial: 7261627
Drug: Estrogen treatment
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen treatment group
Trial: 23994192
Drug: Placebo sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sertraline
Trial: 20515580
Drug: Forskolin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forskolin (10 mg capsule orally per day)
Trial: 12073665
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg bd and clarithromycin 500 mg bd for 14 days